Intas Pharma, Axantia collaborate for Ranibizumab in Middle East

Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US.

Intas Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs.

The Intas Group's revenue amounted to USD 2.2 bn in FY 2020-21 and the compounded annual growth rate of revenue has been 19% in the past 5 years.

Axantia is a pharmaceutical company, established in 2014 as a joint venture between Abu Al Haj Family and Al Faisaliah Group. Axantia develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products in 20 countries across the Middle East, Africa, and the CIS. 

Axantia's subsidiaries – Pharma International Company in Jordan and Med City Pharmaceutical Industries in Saudi Arabia are supported by functional organizations with different manufacturing lines to deliver a broad portfolio covering all major therapeutic areas. Axantia has a general formulations plant in Jeddah and has renovated 3 plants in Amman Jordan; GF plant, Cepha plant and Injectable Cepha plant.